National University of Ireland, Galway

The Regenerative Medicine Institute (REMEDI, is an embedded biomedical research centre with a central focus on the development of novel therapies for human diseases using adult stem cell and/or gene therapies. REMEDI is the leading stem cell research institute in Ireland with an international reputation in translating basic research findings to clinical applications.

It was established at NUI Galway in 2004 as a Science Foundation Ireland-funded Centre for Science, Engineering and Technology with orthopaedic and cardiovascular indications as the primary disease models underpinned with strong basic research programmes on adult stem cells including bone marrow-derived mesenchymal stem cells (BM-MSCs), haematopoietic stem cells, endothelial progenitors, induced pluripotent stem cells and immunology research to underpin cell therapy.

REMEDI currently has focused research programmes in areas such as stem cell biology, immunology, gene therapy and cell manufacturing. To fulfil its translational mission, REMEDI manages and operates the Centre for Cell Manufacturing Ireland (CCMI), a facility licensed by the Irish Medicines Board to manufacture stem cells for human applications.

Researchers at REMEDI have coordinated three European Framework Programme 7-funded projects (Purstem, Reddstar and Visicort) and have partnered on four more (Gamba, Adipoa, Eurostemcell and Decide).

Partner Website

Prof. Frank Barry

Scientific Coordinator of ADIPOA-2

Prof. Frank Barry is the scientific coordinator of ADIPOA-2. He is Professor of Cellular Therapy at NUI Galway, and the Scientific Director of REMEDI since 2004. He has extensive experience in MSC biology and translation and has worked both in academia and industry in the area and directed research and development leading to the first clinical trial worldwide on bone marrow derived MSCs (BM-MSC) in an orthopaedic application while at Osiris Therapeutic Inc., Baltimore, MD, US. The work leading to this trial established the paradigm of trophic action of MSCs on which the current protocol is based. He has over 120 research publications and patents in cellular therapy and mesenchymal stem cell biology

Dr Mary Murphy

Lecturer in Regenerative Medicine and the PI in Orthobiology at REMEDI

Dr Mary Murphy is a Lecturer in Regenerative Medicine and the PI in Orthobiology at REMEDI. Her research interests focus on the biology, mechanism of action, and the use of MSC for tissue regeneration in orthopaedic applications with both academic and industrial experience including translation to human use through a first-in-man clinical trial for BM-MSC. She has extensive experience on isolation, characterization and differentiation of BM-MSC, development of articular cartilage, establishment of animal models and therapeutic modalities for MSC in tissue regeneration with over 60 research publications and patents.